A Multicenter, Open Label Study to Assess the Safety and Efficacy of rIsankizuMab for MaInTenance in Moderate to Severe pLaquE Type pSoriaSis (LIMMITLESS)
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Risankizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms LIMMITLESS
- Sponsors AbbVie
- 31 Jul 2017 Planned number of patients changed from 1900 to 2000.
- 28 Jun 2017 Planned primary completion date changed from 10 Nov 2021 to 30 Nov 2021.
- 13 Feb 2017 New trial record